NCT03400839 Best Clinical Endpoints That Likely Induce Worse Prognosis in Interstitial Lung Diseases Status UNKNOWN Phase N/A
NCT03396120 The FVC/DLCO Ratio is a Useful Predictor of Pulmonary Hypertension in Patients With Interstitial Lung Disease Status COMPLETED Phase N/A
NCT03388580 Predictors for Bronchoalveolar Lavage (BAL) Recovery Rate Derived From Quantified Computed Tomography (qCT) Status COMPLETED Phase N/A
NCT03336736 The Role of Physical Activity and Diet Within Pulmonary Sarcoidosis Status COMPLETED Phase N/A
NCT03297775 Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease Status RECRUITING Phase N/A
NCT03261037 A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period Status COMPLETED Phase NA
NCT03221257 Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate Status COMPLETED Phase PHASE2
NCT03215927 Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease Status COMPLETED Phase PHASE2
NCT03099525 Treatment Outcome and Prognostic Factors for Rheumatoid Arthritis (RA) Patients With Interstitial Lung Disease (ILD) Status UNKNOWN Phase N/A
NCT03040674 An Observational Outcomes Study for Autologous Cell Therapy Among Patients With COPD and Interstitial Lung Disease Status COMPLETED Phase N/A
NCT03018756 Nebulized Fentanyl in Patients With Mild to Moderate Interstitial Lung Disease and Chronic Dyspnea Status COMPLETED Phase PHASE3
NCT02958917 Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis Status TERMINATED Phase PHASE2